S&P 500   4,464.05
DOW   35,281.40
QQQ   366.24
Biden and House Democrats hope to make curbing 'junk fees' a winning issue in 2024
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Yes, inflation is down. No, the Inflation Reduction Act doesn't deserve the credit
Stock market today: Asia follows Wall Street lower after US data revive fears about rate hike
Will I Be Able To Retire At All? Options Expert Weighs In (Ad)
Illinois governor signs ban on firearms advertising allegedly marketed to kids and militants
Don't expect quick fixes in 'red-teaming' of AI models. Security was an afterthought
Holding NVDA? Read This Now (Ad)
US Steel rejects a $7.3 billion offer from rival Cleveland-Cliffs; considers alternatives
Don't expect quick fixes in 'red-teaming' of AI models. Security was an afterthought
S&P 500   4,464.05
DOW   35,281.40
QQQ   366.24
Biden and House Democrats hope to make curbing 'junk fees' a winning issue in 2024
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Yes, inflation is down. No, the Inflation Reduction Act doesn't deserve the credit
Stock market today: Asia follows Wall Street lower after US data revive fears about rate hike
Will I Be Able To Retire At All? Options Expert Weighs In (Ad)
Illinois governor signs ban on firearms advertising allegedly marketed to kids and militants
Don't expect quick fixes in 'red-teaming' of AI models. Security was an afterthought
Holding NVDA? Read This Now (Ad)
US Steel rejects a $7.3 billion offer from rival Cleveland-Cliffs; considers alternatives
Don't expect quick fixes in 'red-teaming' of AI models. Security was an afterthought
S&P 500   4,464.05
DOW   35,281.40
QQQ   366.24
Biden and House Democrats hope to make curbing 'junk fees' a winning issue in 2024
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Yes, inflation is down. No, the Inflation Reduction Act doesn't deserve the credit
Stock market today: Asia follows Wall Street lower after US data revive fears about rate hike
Will I Be Able To Retire At All? Options Expert Weighs In (Ad)
Illinois governor signs ban on firearms advertising allegedly marketed to kids and militants
Don't expect quick fixes in 'red-teaming' of AI models. Security was an afterthought
Holding NVDA? Read This Now (Ad)
US Steel rejects a $7.3 billion offer from rival Cleveland-Cliffs; considers alternatives
Don't expect quick fixes in 'red-teaming' of AI models. Security was an afterthought
S&P 500   4,464.05
DOW   35,281.40
QQQ   366.24
Biden and House Democrats hope to make curbing 'junk fees' a winning issue in 2024
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Yes, inflation is down. No, the Inflation Reduction Act doesn't deserve the credit
Stock market today: Asia follows Wall Street lower after US data revive fears about rate hike
Will I Be Able To Retire At All? Options Expert Weighs In (Ad)
Illinois governor signs ban on firearms advertising allegedly marketed to kids and militants
Don't expect quick fixes in 'red-teaming' of AI models. Security was an afterthought
Holding NVDA? Read This Now (Ad)
US Steel rejects a $7.3 billion offer from rival Cleveland-Cliffs; considers alternatives
Don't expect quick fixes in 'red-teaming' of AI models. Security was an afterthought
NYSE:PKI

Revvity (PKI) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
N/A
50-Day Range
$115.24
▼
$137.11
52-Week Range
N/A
Volume
1.63 million shs
Average Volume
851,117 shs
Market Capitalization
$14.57 billion
P/E Ratio
15.01
Dividend Yield
0.24%
Price Target
$153.29
ProfileAnalyst RatingsDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability

Revvity MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.57 Rating Score
Upside/​Downside
∞ Upside
$153.29 Price Target
Short Interest
N/A
Dividend Strength
Weak
Based on Four Factors
Sustainability
-1.99
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
17.71%
From $4.97 to $5.85 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.88 out of 5 stars

Medical Sector

46th out of 988 stocks

Analytical Instruments Industry

5th out of 29 stocks

See Top Rated MarketRank™ Stocks Here

PKI stock logo

About Revvity (NYSE:PKI) Stock

Revvity, Inc provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. It focuses on translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics.? The company was founded by Richard Scott Perkin and Charles W. Elmer on April 19, 1937, and is headquartered in Waltham, MA.


PKI Stock News Headlines

August 2, 2023 | finance.yahoo.com
Revvity (RVTY) Beats on Q2 Earnings, Lowers '23 EPS View
August 1, 2023 | fool.com
Revvity (NYSE: PKI)
August 14, 2023 | Chaikin Analytics (Ad)
His system isolated NVIDIA - Here's His Next Buy.
Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.
July 31, 2023 | finance.yahoo.com
Revvity (RVTY) to Report Q2 Earnings: What's in the Cards?
May 19, 2023 | finance.yahoo.com
PerkinElmer Completes Transformation to Become Revvity
May 18, 2023 | finance.yahoo.com
Revvity Announces New License Agreement for Next-Generation Base Editing Technology
May 16, 2023 | markets.businessinsider.com
J.P. Morgan Keeps Their Hold Rating on PerkinElmer (PKI)
May 15, 2023 | msn.com
Citigroup Maintains Revvity (PKI) Buy Recommendation
August 14, 2023 | Behind the Markets (Ad)
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
May 15, 2023 | markets.businessinsider.com
Analyst Ratings for Revvity
May 15, 2023 | markets.businessinsider.com
PerkinElmer (PKI) Receives a Buy from Citigroup
May 13, 2023 | msn.com
Barclays Maintains Perkinelmer (PKI) Equal-Weight Recommendation
May 12, 2023 | msn.com
Stifel Maintains Perkinelmer (PKI) Hold Recommendation
May 12, 2023 | msn.com
Baird Maintains Perkinelmer (PKI) Outperform Recommendation
May 12, 2023 | markets.businessinsider.com
Barclays Keeps Their Hold Rating on PerkinElmer (PKI)
May 12, 2023 | markets.businessinsider.com
PerkinElmer (PKI) Gets a Hold from Stifel Nicolaus
May 11, 2023 | seekingalpha.com
Revvity, Inc. 2023 Q1 - Results - Earnings Call Presentation
May 11, 2023 | markets.businessinsider.com
Revvity, Inc. Reveals Increase In Q1 Profit
May 11, 2023 | markets.businessinsider.com
Revvity Now Sees FY23 Results Below View; To Buy Back $600 Mln Of Shares
May 11, 2023 | finance.yahoo.com
Revvity Announces Financial Results for the First Quarter of 2023
May 11, 2023 | finance.yahoo.com
PerkinElmer (PKI) Q1 Earnings Surpass Estimates
May 10, 2023 | markets.businessinsider.com
PerkinElmer earnings: here's what Wall Street expects
May 10, 2023 | bizjournals.com
Here's PerkinElmer's new, post-split name for its life sciences business
May 10, 2023 | msn.com
PerkinElmer Q1 2023 Earnings Preview
May 10, 2023 | finance.yahoo.com
Is a Surprise Coming for Revvity (PKI) This Earnings Season?
May 9, 2023 | finance.yahoo.com
Launching Revvity: A Scientific Solutions Company Powering Innovation from Discovery to Cure
May 9, 2023 | finance.yahoo.com
Waters (WAT) Lags Q1 Earnings and Revenue Estimates
See More Headlines
Receive PKI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Revvity and its competitors with MarketBeat's FREE daily newsletter.

PKI Company Calendar

Last Earnings
5/11/2023
Ex-Dividend for 8/11 Dividend
7/20/2023
Dividend Payable
8/11/2023
Today
8/13/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Analytical instruments
Sub-Industry
Life Sciences Tools & Services
Sector
Medical
Current Symbol
NYSE:PKI
CUSIP
71404610
CIK
31791
Web
www.perkinelmer.com
Phone
(781) 663-6900
Fax
781-663-5985
Employees
16,700
Year Founded
1937

Price Target and Rating

Average Stock Price Forecast
$153.29
High Stock Price Forecast
$165.00
Low Stock Price Forecast
$125.00
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.57
Research Coverage
7 Analysts

Profitability

EPS (Most Recent Fiscal Year)
$7.68
Trailing P/E Ratio
15.01
Forward P/E Ratio
N/A
P/E Growth
0.5
Net Income
$569.18 million
Net Margins
28.94%
Pretax Margin
13.81%
Return on Equity
11.17%
Return on Assets
5.83%

Debt

Debt-to-Equity Ratio
0.48
Current Ratio
2.43
Quick Ratio
2.15

Sales & Book Value

Annual Sales
$3.31 billion
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
9.88
Book Value
$58.49 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
126,410,000
Free Float
125,755,000
Market Cap
$14.57 billion
Optionable
Optionable
Beta
1.10

Social Links

(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Prahlad Ramadhar Singh
    President, Chief Executive Officer & Director
  • Tajinder S. VohraTajinder S. Vohra
    Senior Vice President-Global Operations
  • Maxwell KrakowiakMaxwell Krakowiak
    Chief Financial Officer & Senior Vice President
  • Yi Ping Lin
    Chief Quality, Regulatory & Clinical Officer
  • Jayashree Kailas Thacker
    Chief Information Officer & Senior Vice President

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













PKI Stock - Frequently Asked Questions

Should I buy or sell Revvity stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Revvity in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" PKI shares.
View PKI analyst ratings or view top-rated stocks.

What is Revvity's stock price forecast for 2023?

7 Wall Street research analysts have issued 12-month target prices for Revvity's shares. Their PKI share price forecasts range from $125.00 to $165.00. On average, they predict the company's share price to reach $153.29 in the next twelve months.
View analysts price targets for PKI or view top-rated stocks among Wall Street analysts.

How were Revvity's earnings last quarter?

Revvity, Inc. (NYSE:PKI) issued its quarterly earnings results on Thursday, May, 11th. The medical research company reported $1.01 EPS for the quarter, missing the consensus estimate of $1.07 by $0.06. The medical research company had revenue of $674.87 million for the quarter, compared to the consensus estimate of $686.30 million. Revvity had a trailing twelve-month return on equity of 11.17% and a net margin of 28.94%. During the same period in the previous year, the business earned $2.41 earnings per share.

How often does Revvity pay dividends? What is the dividend yield for Revvity?

Revvity declared a quarterly dividend on Tuesday, April 25th. Stockholders of record on Friday, July 21st will be paid a dividend of $0.07 per share on Friday, August 11th. This represents a $0.28 annualized dividend and a yield of ∞. The ex-dividend date is Thursday, July 20th.
Read our dividend analysis for PKI.

What ETFs hold Revvity's stock?

ETFs with the largest weight of Revvity (NYSE:PKI) stock in their portfolio include AXS Cannabis ETF (THCX) and John Hancock Multifactor Mid Cap ETF (JHMM).VictoryShares WestEnd US Sector ETF (MODL).

Is Revvity a good dividend stock?

Revvity (NYSE:PKI) pays an annual dividend of $0.28 per share and currently has a dividend yield of 0.24%. The dividend payout ratio is 3.65%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, PKI will have a dividend payout ratio of 4.79% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for PKI.

How will Revvity's stock buyback program work?

Revvity declared that its Board of Directors has initiated a share repurchase plan on Thursday, May 11th 2023, which authorizes the company to repurchase $600,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to buy up to 4.1% of its stock through open market purchases. Stock repurchase plans are generally an indication that the company's board of directors believes its shares are undervalued.

What is Prahlad Singh's approval rating as Revvity's CEO?

27 employees have rated Revvity Chief Executive Officer Prahlad Singh on Glassdoor.com. Prahlad Singh has an approval rating of 79% among the company's employees.

What other stocks do shareholders of Revvity own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Revvity investors own include AbbVie (ABBV), Advanced Micro Devices (AMD), NVIDIA (NVDA), Johnson & Johnson (JNJ), Pfizer (PFE), Home Depot (HD), Bristol-Myers Squibb (BMY), CVS Health (CVS), Abbott Laboratories (ABT) and Intel (INTC).

What is Revvity's stock symbol?

Revvity trades on the New York Stock Exchange (NYSE) under the ticker symbol "PKI."

Who are Revvity's major shareholders?

Revvity's stock is owned by many different institutional and retail investors. Top institutional investors include Washington Capital Management Inc. (0.00%). Insiders that own company stock include Andrew Okun, Daniel R Tereau, James M Mock, Maxwell Krakowiak, Prahlad R Singh, Sylvie Gregoire and Tajinder S Vohra.
View institutional ownership trends.

How much money does Revvity make?

Revvity (NYSE:PKI) has a market capitalization of $0.00 and generates $3.31 billion in revenue each year. The medical research company earns $569.18 million in net income (profit) each year or $7.68 on an earnings per share basis.

How many employees does Revvity have?

The company employs 16,700 workers across the globe.

Does Revvity have any subsidiaries?
The following companies are subsidiares of Revvity: 2Cure LLC, Analytica of Branford, Applied Biosystems, Arnel Inc., ArtusLabs, Beijing Huaan Magnech Bio-Tech Co. Ltd., Beijing Meizheng Bio-Tech Co. Ltd., Beijing Meizheng Testing Lab Co. Ltd., Beijing OUMENG Biotechnology Co. Ltd., Bio Evolution SAS, BioLegend, BioLegend CNS Inc., BioLegend China Beijing Ltd., BioLegend Europe B.V., BioLegend France SAS, BioLegend GmbH, BioLegend Inc., BioLegend Japan KK, BioLegend Shenzhen Ltd., BioLegend Taiwan Ltd., BioLegend UK Ltd., BioLegend Ventures LLC, Bioo Scientific Corporation, Biosense Technologies Pvt Ltd., Boulder Diagnostics Europe GmbH, Caliper Life Sciences, Caliper Life Sciences Inc., Cambridge Research & Instrumentation Inc., CambridgeSoft, Ceiba Solutions, Chengdu PerkinElmer Medical Laboratory Co. Ltd., Cisbio Asia Pacific Ltd, Cisbio Bioassays SAS, Cisbio China Ltd., Cisbio.com, DIA.Metra S.R.L., DNA Laboratories Sdn. Bhd., Dani Analitica S.r.l., Dexela, Dharmacon Inc., EUROIMMUN AG, EUROIMMUN Brasil Medicina Diagnostica Ltda., EUROIMMUN Diagnostics España S.L., EUROIMMUN France SAS, EUROIMMUN Hangzhou Medical Laboratory Diagnostics Co. Ltd., EUROIMMUN Italia Diagnostica Medica S.r.l., EUROIMMUN Japan Co. Ltd., EUROIMMUN Medical Diagnostics Canada Inc., EUROIMMUN Medical Diagnostics China Co. Ltd., EUROIMMUN Medical Laboratory Diagnostics South Africa Pty Ltd., EUROIMMUN Medizinische Labordiagnostika AG, EUROIMMUN Polska Sp. z o.o., EUROIMMUN Portugal Unipessoal Lda., EUROIMMUN Schweiz AG, EUROIMMUN South East Asia Pte Ltd., EUROIMMUN Tianjin Medical Diagnostic Technology Co. Ltd., EUROIMMUN Turkey Tibbi Laboratuar Teşhisleri A.Ş., EUROIMMUN UK Ltd., EUROIMMUN US Inc., EUROIMMUN US Real Estate LLC, Geospiza, Guangzhou EUROIMMUN Medical Diagnostic Products Co. Ltd., Hangzhou EUROIMMUN Medical Diagnostic Products Co. Ltd., Horizon Diagnostics Limited, Horizon Discovery, Horizon Discovery Biosciences Limited, Horizon Discovery Group Ltd., Horizon Discovery Inc., Horizon Discovery KK, Horizon Discovery Limited, Horizon Genomics GmbH, IDS Brasil Diagnósticos Ltda., Immunetics Inc., Immunodiagnostic Systems, Immunodiagnostic Systems Deutschland GmbH, Immunodiagnostic Systems France SAS, Immunodiagnostic Systems Holdings Limited, Immunodiagnostic Systems Inc., Immunodiagnostic Systems Limited, Immunodiagnostic Systems SA, Inochem S.A. de C. V., Integromics S.L., Jiangsu Meizheng Bio-Tech Co. Ltd., LabMetrix Technologies, Labtronics, Nexcelom Bioscience, Nexcelom Bioscience Holdings LLC, Nexcelom Bioscience Instruments Shanghai Co. Ltd., Nexcelom Bioscience LLC, Nexcelom Bioscience Ltd., NovaScreen Biosciences Corporation, OZ Systems International SARL, OZ Systems USA LLC, Omni International Inc., Optimization Zorn Corporation, Opto Technology, Orchid Biomedical Systems Pvt Ltd., Oxford Diagnostic Laboratories UK Limited, Oxford Immunotec, Oxford Immunotec Asia Ltd, Oxford Immunotec Global Limited, Oxford Immunotec Ireland Limited, Oxford Immunotec KK, Oxford Immunotec Limited, Oxford Immunotec Shanghai Medical Device Co. Ltd., Oxford Immunotec USA Inc., Pediatrix Medical Group - Newborn Metabolic Screening Business, Perkin Elmer Chile Ltda., Perkin Elmer Instruments Philippines Corporation, Perkin Elmer Italia SpA, Perkin Elmer Sdn. Bhd., Perkin Elmer Yuhan Hoesa, Perkin-Elmer Argentina S.R.L., Perkin-Elmer de Mexico S.A., PerkinElmer Argentina Holdings LLC, PerkinElmer Automotive Research Inc., PerkinElmer BV, PerkinElmer CV Holdings LLC, PerkinElmer Cellular Technologies Germany GmbH, PerkinElmer Danmark A/S, PerkinElmer Diagnostics Global Holdings S.à r.l., PerkinElmer Diagnostics Holdings Inc., PerkinElmer España S.L., PerkinElmer Finance Luxembourg S.à r.l., PerkinElmer Finland Oy, PerkinElmer Genetics Inc., PerkinElmer Genomics Sweden AB, PerkinElmer Germany Diagnostics GmbH, PerkinElmer Global Diagnostics S.C.A., PerkinElmer Global Financing S.à r.l., PerkinElmer Global Holdings S.à r.l., PerkinElmer Health Sciences B.V., PerkinElmer Health Sciences Canada Inc., PerkinElmer Health Sciences FZ-LLC, PerkinElmer Health Sciences Inc., PerkinElmer Health Sciences Puerto Rico LLC, PerkinElmer Health Sciences Pvt Ltd., PerkinElmer Healthcare Diagnostics Shanghai Co. Ltd., PerkinElmer Holding Luxembourg S.à r.l., PerkinElmer Holdings Inc., PerkinElmer Holdings Singapore Pte Ltd., PerkinElmer Hong Kong Ltd., PerkinElmer IVD Pte Ltd., PerkinElmer Inc., PerkinElmer India Pvt Ltd., PerkinElmer Informatics Inc., PerkinElmer Instruments Suzhou Co. Ltd., PerkinElmer International C.V., PerkinElmer Investments Ky, PerkinElmer Ireland Ltd., PerkinElmer Israel Ltd., PerkinElmer Japan Co. Ltd., PerkinElmer LAS Germany GmbH, PerkinElmer LAS UK Ltd., PerkinElmer Life Sciences International Holdings, PerkinElmer Life Sciences Singapore Pte. Ltd., PerkinElmer Limited, PerkinElmer Ltd., PerkinElmer Management Chengdu Co. Ltd., PerkinElmer Management Shanghai Co. Ltd., PerkinElmer Nederland B.V. , PerkinElmer Norge AS, PerkinElmer Oy, PerkinElmer Polska Sp. z o.o., PerkinElmer Pty. Ltd., PerkinElmer SAS, PerkinElmer Sağlık ve Çevre Bilimleri Ltd., PerkinElmer Schweiz AG, PerkinElmer Shanghai Equity Investment Fund L.P., PerkinElmer Shanghai Equity Investment Fund Management Co. Ltd., PerkinElmer Shared Services Sp. z o.o., PerkinElmer Singapore Pte Ltd., PerkinElmer South Africa Pty Ltd., PerkinElmer Sverige AB, PerkinElmer Taiwan Corporation, PerkinElmer UK Holdings Ltd., PerkinElmer VertriebsgmbH, PerkinElmer chemagen Technologie GmbH, PerkinElmer do Brasil Ltda., Perten Instruments, Perten Instruments AB, Perten Instruments GmbH, Perten Instruments of Australia Pty Ltd., Qognit Inc., RHS Ltd, RayAl Ltd., SIRION Biotech, SIRION Biotech GmbH, SIRION Biotech International Inc., Sage Labs LLC, Shandong Meizheng Bio-Tech Co. Ltd., Shanghai Haoyuan Biotech Co. Ltd., Shanghai Spectrum Instruments Co. Ltd., Shanghai Spectrum Instruments Co. Ltd., Signature Genomic Laboratories, Singapore Biosciences Pte Ltd., Solus Scientific Solutions Ltd., SonoVol Inc., Suomen Bioanalytiikka Oy, Surendra Genetic Labs, Suzhou PerkinElmer Medical Laboratory Co. Ltd., Suzhou Sym-Bio LifeScience, Suzhou Sym-Bio Lifescience Co. Ltd., Synthetx Limited, Tulip Diagnostics, Tulip Diagnostics Pvt Ltd., Vanadis Diagnostics, Vanadis Diagnostics AB, ViaCell, ViaCord LLC, VisEn Medical, VisEn Medical Inc., Wallac Oy, Wellesley B.V., Xenogen Corporation, ZeLab SAS, and chemagen Biopolymer-Technologie AG.
Read More
How can I contact Revvity?

Revvity's mailing address is 940 WINTER STREET, WALTHAM MA, 02451. The official website for the company is www.perkinelmer.com. The medical research company can be reached via phone at (781) 663-6900, via email at ir@perkinelmer.com, or via fax at 781-663-5985.

This page (NYSE:PKI) was last updated on 8/14/2023 by MarketBeat.com Staff

My Account -